# EDGAR Filing Document

**Accession Number:** 0001766600
**File Stem:** 0001193125-26-188175
**Filing Date:** 2026-4
**Character Count:** 158661
**Document Hash:** f2f99da6ec058547c06802b093336e95
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-188175.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001193125-26-188175

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 7

**CONFORMED PERIOD OF REPORT**: 20260428

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SNDL Inc.
- **CENTRAL INDEX KEY:** 0001766600
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39005
- **FILM NUMBER:** 26909902

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 17220 STONY PLAIN ROAD NW
- **STREET 2:** SUITE 101
- **CITY:** EDMONTON
- **PROVINCE COUNTRY:** Z4
- **BUSINESS PHONE:** 17809449994

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 17220 STONY PLAIN ROAD NW
- **STREET 2:** SUITE 101
- **CITY:** EDMONTON
- **PROVINCE COUNTRY:** Z4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sundial Growers Inc.
- **DATE OF NAME CHANGE:** 20190131

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2026**

**Commission File Number 001-39005**

**SNDL INC.**

**(Registrant's name)**

**#101, 17220 Stony Plain Road NW**

**Edmonton, AB T5S 1K6**

**Tel.: (780) 944-9994**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☐ Form 40-F ☒

------

**INCORPORATION BY REFERENCE**

This report on Form 6-K shall be deemed to be incorporated by reference in SNDL Inc.'s registration statements on Form S-8 (File No. 333-233156, File No. 333-262233, File No. 333-267510, File No. 333-269242, File No. 333-278683 and File No. 333-286169) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SNDL INC.** | **SNDL INC.** |
| Date: April 28, 2026 | By: | /s/ Alberto Paredero Quiros |
|  | Name: | Alberto Paredero Quiros |
|  | Title: | Chief Financial Officer |

---

**EXHIBIT**

---

| | |
|:---|:---|
| **Exhibit** | **Description of Exhibit** |
| 99.1 | [<u>Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2026</u>](sndl-ex99_1.htm) |
| 99.2 | [<u>Management's Discussion and Analysis for the Three Months Ended March 31, 2026</u>](sndl-ex99_2.htm) |
| 99.3 | [<u>Form 52-109F2 Certificate of Interim Filings by CEO (pursuant to Canadian regulations)</u>](sndl-ex99_3.htm) |
| 99.4 | [<u>Form 52-109F2 Certificate of Interim Filings by CFO (pursuant to Canadian regulations)</u>](sndl-ex99_4.htm) |

---

------

## Exhibit 99.1

**EXHIBIT 99.1**

![img260723042_0.jpg](img260723042_0.jpg)

SNDL Inc.

**Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited – expressed in thousands of Canadian dollars)

------

**SNDL Inc.**

**Condensed Consolidated Interim Statements of Financial Position**

(Unaudited - expressed in thousands of Canadian dollars)

---

| | | | |
|:---|:---|:---|:---|
| As at | Note | **March 31, 2026** | December 31, 2025 |
| **Assets** |  |  |  |
| Current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents |  | **213404** | 252243 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash |  | **20124** | 20081 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities |  | **139** | 84 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable |  | **29059** | 27643 |
| &nbsp;&nbsp;&nbsp;&nbsp;Biological assets | 6 | **2969** | 3120 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 7 | **134982** | 126877 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and deposits |  | **15158** | 15566 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments | 12 | **362** | 484 |
| &nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale |  | **746** | 746 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment in subleases | 10 | **2877** | 2775 |
|  |  | **419820** | 449619 |
| Non-current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term deposits and receivables |  | **2508** | 4526 |
| &nbsp;&nbsp;&nbsp;&nbsp;Right of use assets | 8 | **136852** | 138353 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment | 9 | **149398** | 151900 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment in subleases | 10 | **11244** | 11643 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets | 11 | **57824** | 58520 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments | 12 | **14322** | 11574 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-accounted investees | 13 | **395411** | 385534 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill |  | **127260** | 124248 |
| **Total assets** |  | **1314639** | 1335917 |
| **Liabilities** |  |  |  |
| Current liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities |  | **51799** | 56747 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities | 14 | **34990** | 35462 |
|  |  | **86789** | 92209 |
| Non-current liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities | 14 | **133381** | 134471 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities |  | **6925** | 8041 |
| Total liabilities |  | **227095** | 234721 |
| **Shareholders' equity** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share capital | 15(b) | **2274393** | 2310398 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warrants |  | **306** | 306 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributed surplus |  | **53089** | 54038 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit |  | **(1282860)** | (1302441) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income ("AOCI") |  | **42616** | 38895 |
| Total shareholders' equity |  | **1087544** | 1101196 |
| **Total liabilities and shareholders' equity** |  | **1314639** | 1335917 |

---

Commitments and contingencies (note 23)

See accompanying notes to the condensed consolidated interim financial statements.

------

**SNDL Inc.**

**Condensed Consolidated Interim Statements of Loss and Comprehensive Loss**

(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)

---

| | | | |
|:---|:---|:---|:---|
|  |  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | Note | **2026** | 2025 |
| **Net revenue** | 17 | **195906** | 204914 |
| Cost of sales | 7 | **143094** | 148273 |
| **Gross profit** |  | **52812** | 56641 |
| Investment income | 18 | **1537** | 2856 |
| Share of profit (loss) of equity-accounted investees | 13 | **501** | (4457) |
| General and administrative |  | **46607** | 46359 |
| Sales and marketing |  | **4009** | 3767 |
| Depreciation and amortization | 8911 | **12855** | 13228 |
| Share-based compensation | 16 | **616** | 1388 |
| Restructuring costs |  | **172** | 326 |
| Asset (reversal) impairment, net | 89 | **(178)** | 1984 |
| Other income |  | **(81)** |  |
| Research and development |  | **4** | 100 |
| Gain on disposition of assets |  | **(40)** | (59) |
| **Operating loss** |  | **(9114)** | (12053) |
| Other expenses, net | 19 | **(2294)** | (2654) |
| Loss before income tax |  | **(11408)** | (14707) |
| Income tax recovery |  | **1497** |  |
| **Net loss** |  | **(9911)** | (14707) |
| Equity-accounted investees - share of other comprehensive income (loss) | 13 | **5013** | (348) |
| Investments at fair value through other comprehensive income ("FVOCI") - change in fair value | 12 | **(1292)** | (5230) |
| **Comprehensive loss** |  | **(6190)** | (20285) |
| Net loss per common share attributable to owners of the Company |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | 21 | $**(0.04)** | $(0.06) |

---

See accompanying notes to the condensed consolidated interim financial statements.

------

**SNDL Inc.**

**Condensed Consolidated Interim Statements of Changes in Shareholders' Equity**

(Unaudited - expressed in thousands of Canadian dollars)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  |  | **Accumulated other<br>comprehensive income** | **Accumulated other<br>comprehensive income** |  |
|  | Note | **Share capital** | **Warrants** | **Contributed surplus** | **Accumulated deficit** | **Equity-accounted investees** | **Investments at FVOCI** | **Total** |
| Balance at December 31, 2025 |  | 2310398 | 306 | 54038 | (1302441) | 31673 | 7222 | 1101196 |
| Net loss |  |  |  |  | (9911) |  |  | (9911) |
| Other comprehensive income (loss) |  |  |  |  |  | 5013 | (1292) | 3721 |
| Share repurchases | 15(b) | (38760) |  |  | 29492 |  |  | (9268) |
| Share-based compensation | 16 |  |  | 1806 |  |  |  | 1806 |
| Employee awards exercised |  | 2755 |  | (2755) |  |  |  |  |
| **Balance at March 31, 2026** |  | **2274393** | **306** | **53089** | **(1282860)** | **36686** | **5930** | **1087544** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Balance at December 31, 2024 |  | 2346728 | 667 | 57156 | (1323965) | 50906 | 1864 | 1133356 |
| Net loss |  |  |  |  | (14707) |  |  | (14707) |
| Other comprehensive loss |  |  |  |  |  | (348) | (5230) | (5578) |
| Share repurchases |  | (51714) |  |  | 36383 |  |  | (15331) |
| Share-based compensation | 16 |  |  | 2459 |  |  |  | 2459 |
| Employee awards exercised |  | 93 |  | (93) |  |  |  |  |
| Balance at March 31, 2025 |  | 2295107 | 667 | 59522 | (1302289) | 50558 | (3366) | 1100199 |

---

See accompanying notes to the condensed consolidated interim financial statements.

------

**SNDL Inc.**

**Condensed Consolidated Interim Statements of Cash Flows**

(Unaudited - expressed in thousands of Canadian dollars)

---

| | | | |
|:---|:---|:---|:---|
|  |  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | Note | **2026** | 2025 |
| **Cash provided by (used in):** |  |  |  |
| Operating activities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period |  | **(9911)** | (14707) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments for: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax recovery |  | **(1497)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest and fee income | 18 | **(1482)** | (2856) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of biological assets | 6 | **(46)** | (1447) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of inventory sold |  | **230** | 336 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 16 | **616** | 1388 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 8911 | **14116** | 14187 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on disposition of assets |  | **(40)** | (59) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory impairment and obsolescence | 7 | **1446** | 591 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finance costs, net | 19 | **2062** | 1690 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in estimate of fair value of derivative warrants |  | **—** | (12) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized foreign exchange (gain) loss |  | **(299)** | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset (reversal) impairment, net | 89 | **(178)** | 1984 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share of (profit) loss of equity-accounted investees | 13 | **(501)** | 4457 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on marketable securities | 18 | **(206)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to marketable securities |  | **151** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest received |  | **1361** | 2936 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercise of cash-settled deferred share units | 16(d) | **(474)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in non-cash working capital | 320 | **(1867)** | (713) |
| **Net cash provided by operating activities** |  | **3481** | 7788 |
| Investing activities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to property, plant and equipment | 9 | **(2638)** | (1588) |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to investments | 12 | **(4032)** | (8997) |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments from investments | 12 | **116** | 26907 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital (contributions) distributions from equity-accounted investees | 13 | **(2866)** | 719 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from disposal of property, plant and equipment |  | **43** | 113 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions | 4 | **(2900)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in non-cash working capital | 20 | **911** | 18 |
| **Net cash (used in) provided by investing activities** |  | **(11366)** | 17172 |
| Financing activities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments on lease liabilities, net | 1014 | **(10056)** | (7512) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common shares | 15(b) | **(9575)** | (15031) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in non-cash working capital | 20 | **819** | 91 |
| **Net cash used in financing activities** |  | **(18812)** | (22452) |
| Change in cash and cash equivalents |  | **(26697)** | 2508 |
| Adjustment on initial application of amendments to IFRS 9 on January 1, 2026 |  | **(12142)** |  |
| Cash and cash equivalents, beginning of period |  | **252243** | 218359 |
| Cash and cash equivalents, end of period |  | **213404** | 220867 |

---

See accompanying notes to the condensed consolidated interim financial statements.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

**1.** **Description of business**

SNDL Inc. ("SNDL" or the "Company") was incorporated under the *Business Corporations Act* (Alberta) on August 19, 2006.

The Company's head office is located at 101, 17220 Stony Plain Road NW, Edmonton, Alberta, Canada, T5S 1K6.

The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned, controlled and franchised retail cannabis stores in certain Canadian jurisdictions where the private sale of adult-use cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis in Canada and for export pursuant to the *Cannabis Act* (Canada) (the "Cannabis Act"), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult-use access in Canada.

SNDL and its subsidiaries operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. ("SunStream") (note 13), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.

The Company's liquor retail operations are seasonal in nature. Accordingly, sales will vary by quarter based on consumer spending behaviour. The Company is able to adjust certain variable costs in response to seasonal revenue patterns; however, costs such as occupancy are fixed, causing the Company to report a higher level of earnings in the third and fourth quarters. This business seasonality results in quarterly performance that is not necessarily indicative of the year's performance. The cannabis industry is a growing industry and the Company has not observed significant seasonality as of yet.

The Company's common shares trade on the Nasdaq Capital Market under the ticker symbol "SNDL" and on the Canadian Securities Exchange under the symbol "SNDL".

**U.S. TARIFFS**

In early 2025, the U.S. administration imposed certain tariffs on imports from certain countries, including Canada, and in response, the Canadian administration imposed their own tariffs on certain imports from the United States. Canada and the United States continue ongoing negotiations on a new trade and security relationship, though the scope and terms of such negotiations and the agreements they may produce, if any, are unknown. These tariff announcements and the risk of further potential retaliatory tariffs have created uncertainty, which has permeated the economic and investment outlook, impacting current economic conditions, including such issues as the inflation rate and the global supply chain. Aside from the impact on the global economy, these tariffs may continue to impact SNDL.

SNDL is continuing to monitor the evolving situation and the impacts and potential consequences on its financial position. The Company did not experience a significant impact to its financial performance during the three months ended March 31, 2026.

**2.** **Basis of presentation**

**Statement of compliance**

These condensed consolidated interim financial statements ("financial statements") have been prepared in accordance with International Accounting Standard 34 – Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

annual consolidated financial statements for the year ended December 31, 2025. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2025.

Certain prior period amounts have been reclassified to conform to current year presentation. Specifically, changes to investments have been separated into additions to investments and principal payments from investments and change in fair value of biological assets has been separated into change in fair value of biological assets and change in fair value of inventory sold, both on the condensed consolidated interim statement of cash flows.

These financial statements were approved and authorized for issue by the board of directors of the Company (the "Board") on April 28, 2026.

**3.** **NEW ACCOUNTING STANDARDS**

**Classification and Measurement of Financial Instruments — Amendments to IFRS 9 and IFRS 7**

On January 1, 2026, the Company adopted the amendments to IFRS 9 and IFRS 7 using the prospective application. The amendments include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Clarification on the date of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic payment system.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Clarification and further guidance for assessing whether a financial asset meets the solely payments of principal and interest criterion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•New disclosure requirements for certain instruments without contractual terms that can change cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Updates to the disclosure required for equity instruments designated at FVOCI.

**Impact on adoption**

At March 31, 2026, there was a $5.7 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, which is reflected in the statement of financial position and statement of cash flows. The Company estimated the impact to be approximately $12.1 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, had the amendments been in effect for the annual period ending December 31, 2025.

**4.** **Business acquisitions**

On April 9, 2025, the Company announced that it had entered into an arrangement agreement (the "1CM Agreement") with 1CM Inc. ("1CM") pursuant to which it would acquire 32 cannabis retail stores (the "1CM Transaction") operating under the Cost Cannabis and T Cannabis banners in Ontario, Alberta and Saskatchewan (the "1CM Stores").

Under the terms of the 1CM Agreement, the Company would acquire, with the option to assign, the 1CM Stores for total consideration of $32.2 million cash, subject to certain adjustments at the closing of the 1CM Transaction. The 1CM Stores are comprised of 2 stores in Alberta, 3 stores in Saskatchewan and 27 stores located in Ontario.

The 1CM Transaction is to be completed by way of an arrangement under the *Business Corporations Act* (Ontario). On June 16, 2025, 1CM announced the approval of the 1CM Transaction by 1CM shareholders. On June 18, 2025, 1CM announced that the Ontario Superior Court of Justice (Commercial List) approved the plan of arrangement involving SNDL.

On December 15, 2025, the Company announced that it had entered into an amended and restated arrangement agreement (the "1CM A&R Agreement"). Under the 1CM A&R Agreement, the parties have agreed to, among other things, complete the 1CM Transaction in two stages to align with the status of required provincial regulatory approvals. The aggregate purchase price for the 1CM Transaction has not been amended.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

On January 7, 2026, the first closing ("First Closing") was completed and involved the purchase of 5 cannabis retail stores located in Alberta and Saskatchewan. The purchase price for the First Closing was $5.0 million cash, subject to certain adjustments at the time of the First Closing. Pursuant to the 1CM A&R Agreement, the Company had previously paid a $2.0 million non-refundable cash deposit towards the purchase price in respect of the First Closing.

The second closing ("Second Closing") will involve the purchase of the remaining 27 cannabis retail stores, each of which are located in Ontario. The purchase price for the Second Closing will be $27.2 million cash, subject to certain adjustments at the time of the Second Closing. In addition, the outside date for completion of the 1CM Transaction has been extended from December 31, 2025 to May 31, 2026. The previously paid $1.0 million cash deposit from April 2025 will be applied towards the purchase price in respect of the Second Closing, which is still pending regulatory approval.

The purchase price allocation is not final as the Company continues to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.

Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment. The fair value of consideration paid was as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Provisional** | **Provisional** | **Adjustments** | **Adjustments** | **Provisional** | **Provisional** |
| Cash |  | **5,000** |  | **—** |  | **5,000** |

---

The preliminary fair value of the assets and liabilities acquired was as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Provisional** | **Adjustments** | **Provisional** |
| Inventory | 385 | 22 | 407 |
| Prepaid expenses and deposits | 10 |  | 10 |
| Right of use assets | 554 | 1150 | 1704 |
| Property, plant and equipment | 1172 |  | 1172 |
| Lease liabilities | (435) | (870) | (1305) |
| Total identifiable net assets acquired | 1686 | 302 | 1988 |
| Goodwill | 3314 | (302) | 3012 |
|  | **5000** | **—** | **5000** |

---

Goodwill reflects benefits arising from the acquisition that are not individually identifiable or separately recognizable, including expected operational synergies and future growth opportunities.

As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, the accounting for the acquisition will be revised.

The consolidated financial statements incorporate the operations of the 5 cannabis retail stores located in Alberta and Saskatchewan commencing January 8, 2026. During the period January 8, 2026 to March 31, 2026 the Company recorded revenues of $0.9 million and a net loss of $0.2 million from the 5 cannabis retail stores. Had the First Closing closed on January 1, 2026, management estimates that for the period January 1, 2026, to January 7, 2026, revenue would have increased by $79 thousand and net loss would have increased by $17 thousand. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2026.

The Company incurred costs related to the First Closing of $0.1 million which have been included in transaction costs.

**5.** **Segment information**

The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

Liquor retail includes the sale of wines, beers and spirits through wholly owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis products and accessories through corporate-owned, controlled and franchised retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as "Corporate".

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Intersegment<br>Eliminations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** |
| Total assets | 206508 | 211380 |  | 417888 | 319076 | 410095 | 167580 | 1314639 |
| **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| Net revenue <sup>(1)</sup> | 77345 | 29432 | (14954) | 91823 | 104083 |  |  | 195906 |
| Gross profit | 20352 | 5802 |  | 26154 | 26658 |  |  | 52812 |
| Operating income (loss) | 1116 | (6942) |  | (5826) | (3160) | 2038 | (2166) | (9114) |
| Earnings (loss) before income tax | 554 | (7109) |  | (6555) | (4572) | 2038 | (2319) | (11408) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Company has eliminated $15.0 million for the three months ended March 31, 2026 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Intersegment<br>Eliminations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** |
| Total assets | 219462 | 211625 |  | 431087 | 324447 | 397537 | 182846 | 1335917 |
| **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| Net revenue <sup>(1)</sup> | 77540 | 34319 | (16417) | 95442 | 109472 |  |  | 204914 |
| Gross profit | 19627 | 9211 |  | 28838 | 27803 |  |  | 56641 |
| Operating income (loss) <sup>(2)</sup> | 1327 | (6171) |  | (4844) | (2417) | (1601) | (3191) | (12053) |
| Earnings (loss) before income tax <sup>(2)</sup> | 774 | (6318) |  | (5544) | (3462) | (1601) | (4100) | (14707) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Company has eliminated $16.4 million for the three months ended March 31, 2025 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Recast - refer to description below

In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

The following table presents the effect of the adjustments made to operating income (loss) and earnings (loss) before income tax for the periods indicated.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Intersegment<br>Eliminations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| Operating income (loss) as previously reported | 5162 | (486) |  | 4676 | 1980 | (1601) | (17108) | (12053) |
| Adjustment to general and administrative expenses | (3835) | (5685) |  | (9520) | (4397) |  | 13917 |  |
| Operating income (loss) as recast | 1327 | (6171) |  | (4844) | (2417) | (1601) | (3191) | (12053) |
| Earnings (loss) before income tax as previously reported | 4609 | (633) |  | 3976 | 935 | (1601) | (18017) | (14707) |
| Adjustment to general and administrative expenses | (3835) | (5685) |  | (9520) | (4397) |  | 13917 |  |
| Earnings (loss) before income tax as recast | 774 | (6318) |  | (5544) | (3462) | (1601) | (4100) | (14707) |

---

**Geographical disclosure**

As at March 31, 2026, the Company had non-current assets related to credit investments in the United States of $395.4 million (December 31, 2025 – $385.5 million). For the three months ended March 31, 2026, share of profit of equity-accounted investees related to operations in the United States was a profit of $0.5 million (three months ended March 31, 2025 – loss of $4.5 million). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.

**6.** **biological assets**

The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:

---

| | | |
|:---|:---|:---|
| As at | **March 31, 2026** | December 31, 2025 |
| Balance, beginning of year | **3120** | 1187 |
| Increase in biological assets due to capitalized costs | **4713** | 16082 |
| Net change in fair value of biological assets | **46** | 2322 |
| Transferred to inventory upon harvest | **(4910)** | (16471) |
| Balance, end of period | **2969** | 3120 |

---

Biological assets are valued in accordance with International Accounting Standard 41 – Agriculture and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.

The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.

The Company estimates the harvest yields for cannabis at various stages of growth. As at March 31, 2026, it is estimated that the Company's biological assets will yield approximately 11,785 kilograms (December 31, 2025 – 12,189

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

kilograms) of dry cannabis when harvested. During the three months ended March 31, 2026, the Company harvested 8,941 kilograms of dry cannabis (three months ended March 31, 2025 – 6,736 kilograms).

**7.** **Inventory**

---

| | | |
|:---|:---|:---|
| As at | **March 31, 2026** | December 31, 2025 |
| Retail liquor | **77216** | 75145 |
| Retail cannabis | **15772** | 16348 |
| Harvested cannabis |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Work-in-progress | **2902** | 2203 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finished goods | **5434** | 4342 |
| Manufactured cannabis |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Dried cannabis & biomass | **5397** | 2270 |
| &nbsp;&nbsp;&nbsp;&nbsp;Work in progress | **13871** | 12577 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finished goods | **5566** | 5600 |
| Packaging supplies and consumables | **8824** | 8392 |
|  | **134982** | 126877 |

---

During the three months ended March 31, 2026, inventories of $141.5 million were recognized in cost of sales as an expense (three months ended March 31, 2025 – $148.8 million).

During the three months ended March 31, 2026, the Company recognized inventory write downs of $1.4 million (three months ended March 31, 2025 – $0.6 million).

**8.** **Right of use assets**

---

| | |
|:---|:---|
| **Cost** |  |
| Balance at December 31, 2025 | 270591 |
| Acquisition (note 4) | 1704 |
| Additions | 3858 |
| Renewals, remeasurements and dispositions | 778 |
| **Balance at March 31, 2026** | **276931** |
| **Accumulated depreciation and impairment** |  |
| Balance at December 31, 2025 | 132238 |
| Depreciation | 8141 |
| Impairment reversal | (300) |
| **Balance at March 31, 2026** | **140079** |
| **Net book value** |  |
| Balance at December 31, 2025 | 138353 |
| **Balance at March 31, 2026** | **136852** |

---

For the three months ended March 31, 2026, renewals, remeasurements and dispositions of $0.8 million mainly related to lease renewals for which the Company reassessed likely terms.

For the three months ended March 31, 2026, the Company recorded the following net impairment losses (reversals) on right of use assets:

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

---

| | | | |
|:---|:---|:---|:---|
|  | **Reporting Segment** | **Reporting Segment** |  |
| **Three months ended** | **Liquor retail** | **Cannabis retail** | **Total** |
| March 31, 2026 |  | (300) | (300) |

---

Refer to note 9 for the significant assumptions applied in the impairment test.

For the three months ended March 31, 2025, the Company recorded the following net impairment losses (reversals) on right of use assets:

---

| | | | |
|:---|:---|:---|:---|
|  | **Reporting Segment** | **Reporting Segment** |  |
| **Three months ended** | **Liquor retail** | **Cannabis retail** | **Total** |
| March 31, 2025 |  | (468) | (468) |

---

**9.** **Property, plant and equipment**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Land** | **Production facilities** | **Leasehold improvements** | **Equipment** | **Construction<br>in progress** | **Total** |
| **Cost** |  |  |  |  |  |  |
| Balance at December 31, 2025 | 9454 | 69519 | 84580 | 111672 | 5153 | 280378 |
| Acquisition (note 4) |  |  | 1172 |  |  | 1172 |
| Additions |  | 29 | 64 | 1313 | 321 | 1727 |
| Transfers from CIP |  |  | 785 | 26 | (811) |  |
| Dispositions |  |  |  |  |  |  |
| **Balance at March 31, 2026** | **9454** | **69548** | **86601** | **113011** | **4663** | **283277** |
| **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** | **Accumulated depreciation and impairment** |
| Balance at December 31, 2025 | 689 | 11567 | 45907 | 70315 |  | 128478 |
| Depreciation | 750 | 120 | 2188 | 2221 |  | 5279 |
| Impairment (recovery) |  | 475 | (277) | (76) |  | 122 |
| Dispositions |  |  |  |  |  |  |
| **Balance at March 31, 2026** | **1439** | **12162** | **47818** | **72460** | **—** | **133879** |
| **Net book value** |  |  |  |  |  |  |
| Balance at December 31, 2025 | 8765 | 57952 | 38673 | 41357 | 5153 | 151900 |
| **Balance at March 31, 2026** | **8015** | **57386** | **38783** | **40551** | **4663** | **149398** |

---

During the three months ended March 31, 2026, depreciation expense of $1.3 million was capitalized to biological assets and inventory (three months ended March 31, 2025 – $1.0 million).

During the three months ended March 31, 2026, the Company determined that indicators of impairment existed relating to the Stellarton facility due to slow moving market conditions. The estimated recoverable amount of the facility was determined to be its fair value less costs of disposal and an impairment of $0.5 million was recorded to write down the facility to its recoverable amount of $1.9 million. The fair value measurement is categorized within Level 3 of the fair value hierarchy. The impairment was recognized in the Company's cannabis operations reporting segment.

During the three months ended March 31, 2026, the Company determined that indicators of impairment reversal existed relating to one cannabis retail store and three liquor retail stores showing improved store level operating results. For impairment testing of retail property, plant and equipment and right of use assets, the Company determined that a cash generating unit ("CGU") was defined as each individual retail store. The Company completed impairment tests for each CGU determined to have an indicator of potential impairment or impairment reversal using a discounted cash flow model. The recoverable amounts for each CGU were based on the higher of its estimated value

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

in use and fair value less costs of disposal using Level 3 inputs. The significant assumptions applied in the impairment test are described below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Cash flows: Projected future sales and earnings for cash flows are based on actual operating results and operating forecasts. Management determined forecasted growth rates of sales based on past performance, expectations of future performance for each location and industry averages. Expenditures were based upon a combination of historical percentages of revenue, sales growth rates, forecasted inflation rates and contractual lease payments. The duration of the cash flow projections for individual CGUs is 5 years or based on the remaining lease term of the CGU.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Discount rate: A pre-tax discount rate range of 11.0% – 13.5% was estimated and is based on market assessments of the time value of money and CGU specific risks to determine the weighted average cost of capital for the given CGU.

For the three months ended March 31, 2026, the Company recorded the following net impairment losses (reversals) on retail property, plant and equipment:

---

| | | | |
|:---|:---|:---|:---|
|  | **Reporting Segment** | **Reporting Segment** |  |
| **Three months ended** | **Liquor retail** | **Cannabis retail** | **Total** |
| March 31, 2026 | (171) | (182) | (353) |

---

The Company also recorded impairment losses and impairment reversals on right of use assets (note 8).

For the three months ended March 31, 2025, the Company recorded the following net impairment losses (reversals) on retail property, plant and equipment:

---

| | | | |
|:---|:---|:---|:---|
|  | **Reporting Segment** | **Reporting Segment** |  |
| **Three months ended** | **Liquor retail** | **Cannabis retail** | **Total** |
| March 31, 2025 |  | (263) | (263) |

---

**10.** **Net investment in subleases**

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | December 31, 2025 |
| Balance, beginning of year | **14418** | 18186 |
| Finance income | **137** | 612 |
| Rents recovered (payments made directly to landlords) | **(837)** | (3342) |
| Dispositions and remeasurements | **403** | (1038) |
| Balance, end of period | **14121** | 14418 |
| Current portion | **2877** | 2775 |
| Long-term | **11244** | 11643 |

---

Net investment in subleases represent leased retail stores that have been subleased to certain franchise partners. These subleases are classified as a finance lease as the sublease terms are for the remaining term of the head lease.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

**11.** **Intangible assets**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Brands and trademarks** | **Franchise agreements** | **Software** | **Retail<br>licenses** | **Total** |
| **Cost** |  |  |  |  |  |
| Balance at December 31, 2025 | 81900 | 10000 | 5589 | 6482 | 103971 |
| **Balance at March 31, 2026** | **81900** | **10000** | **5589** | **6482** | **103971** |
| **Accumulated amortization and impairment** |  |  |  |  |  |
| Balance at December 31, 2025 | 35792 | 5564 | 3365 | 730 | 45451 |
| Amortization | 43 | 308 | 224 | 121 | 696 |
| **Balance at March 31, 2026** | **35835** | **5872** | **3589** | **851** | **46147** |
| **Net book value** |  |  |  |  |  |
| Balance at December 31, 2025 | 46108 | 4436 | 2224 | 5752 | 58520 |
| **Balance at March 31, 2026** | **46065** | **4128** | **2000** | **5631** | **57824** |

---

**12.** **Investments**

---

| | | | | |
|:---|:---|:---|:---|:---|
| As at | **March 31, 2026** | **March 31, 2026** | December 31, 2025 | December 31, 2025 |
| Investments at amortized cost |  | **708** |  | 822 |
| Investments at FVOCI |  | **13,976** |  | 11,236 |
|  |  | **14,684** |  | 12,058 |
| Current portion |  | **362** |  | 484 |
| Long-term |  | **14,322** |  | 11,574 |

---

**Investments at amortized cost**

The Company has loans outstanding to franchise partners with a total balance of $0.7 million, maturity dates ranging from August 2026 to June 2030, and annual interest rates ranging from 7.5% – 8%.

**Investments at fAIR vALUE tHROUGH OTHER COMPREHENSIVE INCOME**

During the three months ended March 31, 2026, the Company acquired an additional $4.0 million of investments in listed common shares that are not held for trading, for which the Company irrevocably elected at initial recognition to designate at fair value through other comprehensive income. The shares were marked to market to $14.0 million as a Level 1 investment and the corresponding $1.3 million loss was recognized in other comprehensive income.

**13.** **Equity-accounted investees**

---

| | | | | |
|:---|:---|:---|:---|:---|
| As at | **March 31, 2026** | **March 31, 2026** | December 31, 2025 | December 31, 2025 |
| Interest in joint venture |  | **395,411** |  | 385,534 |

---

SunStream is a joint venture in which the Company has a 50% ownership interest. SunStream is a private company, incorporated under the *Business Corporations Act* (Alberta), which provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities.

SunStream is structured separately from the Company, and the Company has a residual interest in the net assets of SunStream. Accordingly, the Company has classified its interest in SunStream as a joint venture, which is accounted for using the equity-method.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

The current investment portfolio of SunStream is comprised of secured debt, hybrid debt, derivative instruments and convertible equity instruments with United States based cannabis businesses. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss. SunStream actively monitors these investments for changes in credit risk, market risk and other risks specific to each investment.

The following table summarizes the carrying amount of the Company's interest in the joint venture:

---

| | |
|:---|:---|
|  | Carrying amount |
| Balance at December 31, 2025 | 385534 |
| Share of net earnings | 501 |
| Share of other comprehensive income (taxes at 23%) | 6510 |
| Capital contributions | 2866 |
| **Balance at March 31, 2026** | **395411** |

---

SunStream is a related party due to it being classified as a joint venture of the Company. Capital contributions to the joint venture and distributions received from the joint venture are classified as related party transactions.

The following table summarizes the financial information of SunStream:

---

| | | |
|:---|:---|:---|
| As at | **March 31, 2026** | March 31, 2025 |
| Current assets (including cash and cash equivalents - 2026: $0.2 million, 2025: $0.7 million) | **3174** | 2058 |
| Non-current assets | **373912** | 402960 |
| Current liabilities | **(10088)** | (1144) |
| Net assets (liabilities) (100%) | **366998** | 403874 |
| Three months ended March 31 | **2026** | 2025 |
| Revenue (loss) | **1131** | (3874) |
| Profit (loss) from operations | **724** | (4245) |
| Other comprehensive income (loss) | **6510** | (348) |
| Total comprehensive income (loss) | **7192** | (4539) |

---

**14.** **Lease Liabilities**

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | December 31, 2025 |
| Balance, beginning of year | **169933** | 152273 |
| Acquisition (note 4) | **1305** |  |
| Additions | **3917** | 9634 |
| Lease payments | **(10893)** | (42587) |
| Renewals, remeasurements and dispositions | **1132** | 42790 |
| Tenant inducement allowances received | **804** | 303 |
| Accretion expense | **2173** | 7520 |
| Balance, end of period | **168371** | 169933 |
| Current portion | **34990** | 35462 |
| Long-term | **133381** | 134471 |

---

For the three months ended March 31, 2026, renewals, remeasurements and dispositions of $1.1 million mainly related to lease renewals for which the Company reassessed likely terms.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

The following table presents the contractual undiscounted cash flows, excluding periods covered by lessee lease extension options that have been included in the determination of the lease term, related to the Company's lease liabilities as at March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** |
| Less than one year |  | 43,711 |
| One to three years |  | 72,651 |
| Three to five years |  | 50,174 |
| Thereafter |  | 11,120 |
| Minimum lease payments |  | 177,656 |

---

**15.** **Share capital and warrants**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A)** **Authorized**

The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B)** **Issued and outstanding**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **March 31, 2026** | **March 31, 2026** | December 31, 2025 | December 31, 2025 |
|  | Note | **Number of<br>Shares** | **Carrying<br>Amount** | Number of<br>Shares | Carrying<br>Amount |
| Balance, beginning of year |  | **263359123** | **2310398** | 263021847 | 2346728 |
| Share repurchases |  | **(4453358)** | **(38760)** | (5899897) | (52688) |
| Employee awards exercised |  | **1265453** | **2755** | 6237173 | 16358 |
| Balance, end of period |  | **260171218** | **2274393** | 263359123 | 2310398 |

---

During the three months ended March 31, 2026, the Company purchased and cancelled 4.5 million common shares, pursuant to its repurchase program, at a weighted average price, excluding commissions, of $2.13 (US$1.56) per common share for a total cost of $9.6 million including commissions. Accumulated deficit was reduced by $29.5 million, representing the excess of the average carrying value of the common shares over their purchase price.

**16.** **Share-based compensation**

The Company has a number of share-based compensation plans which include simple and performance warrants, stock options, restricted share units ("RSUs") and deferred share units ("DSUs"). During 2019, the Company established the stock option, RSU and DSU plans to replace the granting of simple warrants and performance warrants.

The components of share-based compensation expense are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | **2026** | 2025 |
| Equity-settled expense |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted share units (C) | **1806** | 2459 |
| Cash-settled (recovery) expense |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred share units <sup>(1)</sup> (D) | **(1190)** | (1071) |
|  | **616** | 1388 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company's common shares at each period end. Fluctuations in the fair value are recognized during the period in which they occur.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

**Equity-settled plans**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A)** **Simple and performance warrants**

The Company issued simple warrants and performance warrants to employees, directors and others at the discretion of the Board. Simple and performance warrants granted generally vest annually over a three-year period, simple warrants expire five years after the grant date and performance warrants expire five years after vesting criteria are met.

The following table summarizes changes in the simple and performance warrants during the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Simple<br>warrants<br>outstanding** | **Weighted<br>average<br>exercise price** | **Performance<br>warrants<br>outstanding** | **Weighted<br>average<br>exercise price** |
| Balance at December 31, 2025 | 16320 | $64.32 | 20800 | $40.38 |
| Forfeited | (320) | 155.19 |  | 0.00 |
| Expired |  | 0.00 | (12800) | 18.75 |
| Balance at March 31, 2026 | **16000** | $**62.50** | **8000** | $**75.00** |

---

The following table summarizes outstanding simple and performance warrants as at March 31, 2026:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Warrants outstanding** | **Warrants outstanding** | **Warrants outstanding** | **Warrants exercisable** | **Warrants exercisable** | **Warrants exercisable** |
| Range of exercise prices | Number of<br>warrants | Weighted<br>average<br>exercise<br>price | Weighted<br>average<br>contractual<br>life (years) | Number of<br>warrants | Weighted<br>average<br>exercise<br>price | Weighted<br>average<br>contractual<br>life (years) |
| **Simple warrants** |  |  |  |  |  |  |
| $62.50 - $93.75 | 16000 | $62.50 | 0.78 | 16000 | $62.50 | 0.78 |
| **Performance warrants** |  |  |  |  |  |  |
| $62.50 - $93.75 | 8000 | $75.00 | n/a |  | $— | n/a |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B)** **Stock options**

The Company issues stock options to employees and others at the discretion of the Board. Stock options granted generally vest annually over a three-year period and generally expire ten years after the grant date.

The following table summarizes changes in stock options during the three months ended March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **Stock options outstanding** | **Weighted<br>average<br>exercise price** |
| Balance at December 31, 2025 | 320951 | $11.86 |
| Forfeited | (236853) | 11.79 |
| Balance at March 31, 2026 | **84098** | $**12.05** |

---

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes outstanding stock options as at March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Stock options outstanding** | **Stock options outstanding** | **Stock options exercisable** | **Stock options exercisable** |
| Exercise prices | Number of<br>options | Weighted<br>average<br>contractual<br>life (years) | Number of<br>options | Weighted<br>average<br>contractual<br>life (years) |
| $11.50 | 10000 | 4.16 | 10000 | 4.16 |
| $11.79 | 64738 | 0.80 | 64738 | 0.80 |
| $11.90 | 8160 | 4.24 | 8160 | 4.24 |
| $31.50 | 1200 | 1.73 | 1200 | 1.73 |
|  | **84098** | **1.55** | **84098** | **1.55** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C)** **Restricted share units**

RSUs are granted to employees and the vesting requirements and maximum term are at the discretion of the Board. RSUs are exchangeable for an equal number of common shares.

The following table summarizes changes in RSUs during the three months ended March 31, 2026:

---

| | |
|:---|:---|
|  | **RSUs<br>outstanding** |
| Balance at December 31, 2025 | 6855023 |
| Granted | 3699608 |
| Forfeited | (599755) |
| Exercised | (1265453) |
| Balance at March 31, 2026 | **8689423** |

---

At March 31, 2026, no RSUs were vested or exercisable.

**Cash-settled plans**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D)** **Deferred share units**

DSUs are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder equal to the fair value of the Company's common shares calculated at the date of such payment.

The DSU plan was amended for grants made in 2025 and onward, allowing directors who have met the Company's share ownership guidelines to select a redemption date based on specific criteria. All DSUs granted prior to December 31, 2024 can only be exercised once a director ceases to be on the Board. The fair value of DSUs that will be redeemed within the next year are classified as a current liability within accounts payable.

As at March 31, 2026, the Company recognized a liability of $6.5 million relating to the fair value of cash-settled DSUs (December 31, 2025 – $8.1 million) with $6.4 million (December 31, 2025 – $7.6 million) included as a non-current liability within other liabilities and $0.1 million (December 31, 2025 – $0.5 million) included as a current liability within accounts payable.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes changes in DSUs during the three months ended March 31, 2026:

---

| | |
|:---|:---|
|  | **DSUs<br>outstanding** |
| Balance at December 31, 2025 | 3568503 |
| Granted | 157107 |
| Exercised | (217602) |
| Balance at March 31, 2026 | **3508008** |

---

At March 31, 2026, 3.51 million DSUs were vested (December 31, 2025 – 3.57 million) and 0.1 million were exercisable (December 31, 2025 – 0.3 million).

**17.** **NET revenue**

Liquor retail revenue is derived from the sale of wines, beers and spirits to customers and proprietary licensing. Cannabis retail revenue is derived from retail cannabis sales to customers, proprietary licensing, franchise revenue consisting of royalty and franchise fee revenue, and other revenue consisting of millwork, supply and accessories revenue. Cannabis operations revenue is derived from contracts with customers and is comprised of sales to provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, provision of proprietary cannabis processing services, product development, manufacturing and commercialization of cannabis consumer products and sales to medical customers.

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | **2026** | 2025 |
| Liquor retail revenue |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Retail | **103696** | 109022 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proprietary licensing | **387** | 450 |
| Liquor retail revenue | **104083** | 109472 |
| Cannabis retail revenue |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Retail | **72449** | 72256 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proprietary licensing | **3865** | 4077 |
| &nbsp;&nbsp;&nbsp;&nbsp;Franchise | **1031** | 1207 |
| Cannabis retail revenue | **77345** | 77540 |
| Cannabis operations revenue |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Provincial boards | **32577** | 34855 |
| &nbsp;&nbsp;&nbsp;&nbsp;Wholesale | **7586** | 11483 |
| &nbsp;&nbsp;&nbsp;&nbsp;Analytical testing and other | **108** | 204 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intersegment eliminations | **(14954)** | (16417) |
| Cannabis operations revenue | **25317** | 30125 |
| Gross revenue | **206745** | 217137 |
| Excise taxes <sup>(1)</sup> | **10839** | 12223 |
| Net revenue | **195906** | 204914 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Excise tax is only applicable to cannabis operations provincial board revenue.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

**18.** **Investment income**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | **2026** | **2026** | 2025 | 2025 |
| Interest income from investments at amortized cost |  | **14** |  | 1,373 |
| Interest income from cash |  | **1,468** |  | 1,483 |
| Gain on marketable securities |  | **55** |  |  |
|  |  | **1,537** |  | 2,856 |

---

**19.** **Other (expenses) INCOME, NET**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | **2026** | 2025 |
| Finance (costs) income |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accretion on lease liabilities | **(2173)** | (1830) |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial guarantee liability recovery | **12** | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other finance costs | **(38)** | (41) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | **137** | 167 |
| Total finance costs | **(2062)** | (1690) |
| Change in fair value of derivative warrants | **—** | 12 |
| Transaction costs | **(341)** | (778) |
| Foreign exchange loss | **109** | (198) |
|  | **(2294)** | (2654) |

---

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

**20.** **SUPPLEMENTAL CASH FLOW DISCLOSURES**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | **2026** | 2025 |
| Cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **10802** | (1591) |
| &nbsp;&nbsp;&nbsp;&nbsp;Biological assets | **197** | (751) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | **(9374)** | (5571) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and deposits | **321** | 5979 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments | **—** | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;Right of use assets | **(3859)** | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment | **911** | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | **(3856)** | 1244 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities | **4721** | 62 |
|  | **(137)** | (604) |
| Changes in non-cash working capital relating to: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating | **(1867)** | (713) |
| &nbsp;&nbsp;&nbsp;&nbsp;Investing | **911** | 18 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing | **819** | 91 |
|  | **(137)** | (604) |

---

**21.** **Earnings (Loss) per share**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
|  | **2026** | 2025 |
| Weighted average shares outstanding (000s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted <sup>(1)</sup> | **261299** | 259127 |
| Net loss attributable to owners of the Company | **(9911)** | (14707) |
| Per share - basic and diluted | $**(0.04)** | $(0.06) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)For the three months ended March 31, 2026, there were 54.4 thousand equity classified warrants, 16.0 thousand simple warrants, 8.0 thousand performance warrants, 0.1 million stock options and 8.7 million RSUs that were excluded from the calculation as the impact was anti-dilutive (three months ended March 31, 2025 – 118.4 thousand equity classified warrants, 50.0 thousand derivative warrants, 37.6 thousand simple warrants, 24.8 thousand performance warrants, 0.6 million stock options and 13.3 million RSUs).

**22.** **Financial instruments**

The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, investments at amortized cost, investments at FVOCI and accounts payable and accrued liabilities.

**Fair value**

The carrying value of cash and cash equivalents, restricted cash, accounts receivable and accounts payable and accrued liabilities approximate their fair value due to the short-term nature of the instruments. The carrying value of investments at amortized cost approximate their fair value as the fixed interest rates approximate market rates for comparable transactions.

------

**SNDL Inc.**

**Notes to the Condensed Consolidated Interim Financial Statements**

For the three months ended March 31, 2026

(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)

Fair value measurements of marketable securities, investments at FVOCI and derivative warrants are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | Fair value measurements using | Fair value measurements using | Fair value measurements using |
| **March 31, 2026** | Carrying<br>amount | Level 1 | Level 2 | Level 3 |
| Recurring measurements: |  |  |  |  |
| Financial assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | **139** | **139** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments at FVOCI | **13976** | **13976** |  |  |
|  |  | Fair value measurements using | Fair value measurements using | Fair value measurements using |
| December 31, 2025 | Carrying<br>amount | Level 1 | Level 2 | Level 3 |
| Recurring measurements: |  |  |  |  |
| Financial assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 84 | 84 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments at FVOCI | 11236 | 11236 |  |  |

---

There were no transfers between Levels 1, 2 and 3 inputs during the period.

**23.** **Commitments and contingencies**

The following table summarizes contractual commitments at March 31, 2026:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Less than<br>one year** | **One to three<br>years** | **Three to five<br>years** | **Thereafter** | **Total** |
| Accounts payable and accrued liabilities | 51799 |  |  |  | 51799 |
| Financial guarantee liability |  | 135 |  |  | 135 |
| Loyalty liability |  | 388 |  |  | 388 |
| Balance, end of year | **51799** | **523** |  |  | **52322** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A)** **Commitments**

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B)** **Contingencies**

From time to time, the Company and its subsidiaries are or may become involved in various legal claims and actions which arise in the ordinary course of their business and operations. While the outcome of any such claim or action is inherently uncertain, after consulting with counsel, the Company believes that the losses that may result, if any, will not be material to the consolidated financial statements.

------

## Exhibit 99.2

**EXHIBIT 99.2**

![img261646563_0.jpg](img261646563_0.jpg)

SNDL Inc.

**Management's Discussion and Analysis** 

For the three months ended March 31, 2026

------

**Management's Discussion and Analysis**

*This Management's Discussion and Analysis ("MD&A") of the financial condition and performance of SNDL Inc. ("SNDL" or the "Company") for the three months ended March 31, 2026 is dated April 28, 2026. This MD&A should be read in conjunction with the Company's condensed consolidated interim financial statements and the notes thereto for the three months ended March 31, 2026 (the "Interim Financial Statements") and the audited consolidated financial statements and notes thereto for the year ended December 31, 2025 (the "Audited Financial Statements") and the risks identified in the Company's Annual Information Form for the year ended December 31, 2025 (the "AIF") and elsewhere in this MD&A. This MD&A has been prepared in accordance with National Instrument 51-102 - Continuous Disclosure Obligations and is presented in thousands of Canadian dollars, except where otherwise indicated.*

**MD&A – Table of Contents**

---

| | |
|:---|:---|
| [<u>COMPANY OVERVIEW</u>](#company_overview) | 1 |
| [<u>RECENT DEVELOPMENTS</u>](#recent_developments) | 2 |
| [<u>Other developments</u>](#other_developments) | 3 |
| [<u>FINANCIAL HIGHLIGHTS</u>](#financial_highlights) | 4 |
| [<u>CONSOLIDATED RESULTS</u>](#consolidated_results) | 4 |
| [<u>OPERATING SEGMENTS</u>](#operating_segments) | 5 |
| [<u>LIQUOR RETAIL SEGMENT RESULTS</u>](#liquor_retail_segment_results) | 7 |
| [<u>CANNABIS RETAIL SEGMENT RESULTS</u>](#cannabis_retail_segment_result) | 8 |
| [<u>CANNABIS OPERATIONS SEGMENT RESULTS</u>](#cannabis_operations_segment_results) | 9 |
| [<u>INVESTMENTS SEGMENT RESULTS</u>](#investments_segment_results) | 10 |
| [<u>SELECTED QUARTERLY INFORMATION</u>](#selected_quarterly_information) | 10 |
| [<u>LIQUIDITY AND CAPITAL RESOURCES</u>](#liquidity_and_capital_resources) | 11 |
| [<u>CONTRACTUAL COMMITMENTS AND CONTINGENCIES</u>](#contractual_commitments) | 14 |
| [<u>NON-IFRS FINANCIAL MEASURES AND OTHER MEASURES</u>](#non_ifrs_financial_measures) | 14 |
| [<u>RELATED PARTIES</u>](#related_parties) | 16 |
| [<u>OFF BALANCE SHEET ARRANGEMENTS</u>](#off_balance_sheet) | 16 |
| [<u>CRITICAL ACCOUNTING ESTIMATES</u>](#critical_accounting) | 16 |
| [<u>NEW ACCOUNTING PRONOUNCEMENTS</u>](#new_accounting) | 17 |
| [<u>RISK FACTORS</u>](#risk_factors) | 18 |
| [<u>DISCLOSURE CONTROLS AND PROCEDURES</u>](#disclosure_controls) | 18 |
| [<u>INTERNAL CONTROL OVER FINANCIAL REPORTING</u>](#internal_control) | 18 |
| [<u>CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</u>](#changes_in) | 18 |
| [<u>ABBREVIATIONS</u>](#abbreviations) | 18 |
| [<u>FORWARD-LOOKING INFORMATION</u>](#forward_looking) | 19 |
| [<u>ADDITIONAL INFORMATION</u>](#additional_information) | 20 |

---

------

# COMPANY OVERVIEW
SNDL operates under four reportable segments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Liquor retail sales of wines, beers and spirits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Cannabis retail sales of cannabis products and accessories through corporate-owned, controlled and franchised cannabis retail operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Cannabis operations as a licensed producer that grows cannabis using indoor facilities and manufactures cannabis products, providing proprietary cannabis processing services; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Investments targeting the cannabis industry.

The principal activities of the Company are: (i) the retailing of wines, beers and spirits under the *Wine and Beyond*, *Ace Liquor* and *Liquor Depot* retail banners; (ii) the operation and support of corporate-owned, controlled and franchised retail cannabis stores in certain Canadian jurisdictions where the private sale of adult-use cannabis is permitted, under the *Value Buds* and *Spiritleaf* retail banners; (iii) the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis in Canada and for export pursuant to the *Cannabis Act* (Canada) (the "Cannabis Act") through an owned and licensed cannabis brand portfolio that includes *Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Grasslands, Pearls by Grön, No Future* and *Bhang Chocolate*; and (iv) the provision of financial services through the deployment of capital to direct and indirect investments and partnerships throughout the cannabis industry. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult-use access in Canada.

The Company produces and markets cannabis products for the Canadian adult-use market and for the international medicinal market. SNDL's operations cultivate cannabis using approximately 380,000 square feet of total space in Atholville, New Brunswick. SNDL's extraction and manufacturing operations include approximately 74,100 square feet of total space in British Columbia and approximately 65,500 square feet of total space in Ontario.

SNDL and its subsidiaries operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. ("SunStream"), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The current investment portfolio of SunStream is comprised of secured debt, hybrid debt, derivative instruments and convertible equity instruments issued by United States based cannabis businesses. The Company also makes strategic portfolio investments in debt and equity securities.

SNDL was incorporated under the *Business Corporations Act* (Alberta) (the "ABCA") on August 19, 2006. The Company's common shares are listed under the symbol "SNDL" on the Nasdaq Capital Market (the "Nasdaq") and the Canadian Securities Exchange (the "CSE").

SNDL is headquartered in Edmonton, Alberta, with operations in Kelowna, British Columbia, Bolton, Ontario, London, Ontario, Toronto, Ontario and Atholville, New Brunswick, and corporate-owned, controlled and franchised retail liquor and cannabis stores in five provinces across Canada.

SNDL's overall strategy is to build sustainable, long-term shareholder value by improving liquidity and cost of capital while optimizing the capacity and capabilities of its production facilities in the creation of a consumer-centric brand and product portfolio. SNDL's retail operations will continue to build a Canadian retail liquor brand and a network of retail cannabis stores across Canadian jurisdictions where the private distribution of cannabis is legal. SNDL's investment operations seek to deploy capital through direct and indirect investments and partnerships throughout the cannabis industry.

------

# RECENT DEVELOPMENTS
**LEADERSHIP TRANSITION FOR CANNABIS SEGMENT**

On March 30, 2026, the Company announced that Tyler Robson, President of Cannabis, had left the Company in order to pursue other opportunities. Ryan Hellard, the Company's current Chief Strategy Officer, assumed the role of Interim President of Cannabis.

**cannabis operations**

The Company entered into a license and manufacturing agreement with Jeeter in September 2025 with an anticipated launch in Q2 2026. The first purchase orders came through in March 2026 with the official launch occurring in April 2026.

Jeeter is a fast growing brand in the pre-roll category known for their quad infused pre-rolls. Jeeter is based in California where they operate an 18,000 square foot facility to manufacture, fulfill, produce and distribute their product lineup.

**Rise Rewards Loyalty Program**

On April 22, 2025, the Company announced the launch of its Rise Rewards loyalty program, designed to help Value Buds customers save more, earn more, and get even more from every visit. Rise Rewards is available at all Value Buds locations in Alberta, Ontario, Saskatchewan, and Manitoba. Customers can earn points with every visit and by participating in the Company's recycling initiative, reinforcing Value Buds' commitment to affordability, sustainability, and customer appreciation. By leveraging insights from Rise Rewards, the Company aims to optimize Value Buds' pricing strategies and marketing efforts to provide superior customer experiences.

On March 10, 2026, the Company launched Rise Rewards at all Ace Liquor and Liquor Depot locations in Alberta. Rise Rewards is expected to launch at Wine and Beyond locations in 2026.

**acquisition of cost cannabis and t cannabis locations from 1cm**

On April 9, 2025, the Company announced that it had entered into an arrangement agreement (the "1CM Agreement") with 1CM Inc. ("1CM") pursuant to which it would acquire 32 cannabis retail stores (the "1CM Transaction") operating under the Cost Cannabis and T Cannabis banners in Ontario, Alberta and Saskatchewan (the "1CM Stores").

Under the terms of the 1CM Agreement, the Company would acquire, with the option to assign, the 1CM Stores for total consideration of $32.2 million cash, subject to certain adjustments at the closing of the 1CM Transaction. The 1CM Stores are comprised of 2 stores in Alberta, 3 stores in Saskatchewan and 27 stores located in Ontario.

The 1CM Transaction is to be completed by way of an arrangement under the *Business Corporations Act* (Ontario). On June 16, 2025, 1CM announced the approval of the 1CM Transaction by 1CM shareholders. On June 18, 2025, 1CM announced that the Ontario Superior Court of Justice (Commercial List) approved the plan of arrangement involving SNDL.

On December 15, 2025, the Company announced that it had entered into an amended and restated arrangement agreement (the "1CM A&R Agreement"). Under the 1CM A&R Agreement, the parties have agreed to, among other things, complete the 1CM Transaction in two stages to align with the status of required provincial regulatory approvals. The aggregate purchase price for the 1CM Transaction has not been amended.

On January 7, 2026, the first closing ("First Closing") was completed and involved the purchase of 5 cannabis retail stores located in Alberta and Saskatchewan. The purchase price for the First Closing was $5.0 million cash, subject to certain adjustments at the time of the First Closing. Pursuant to the 1CM A&R Agreement, the Company had previously paid a $2.0 million non-refundable cash deposit towards the purchase price in respect of the First Closing.

The second closing ("Second Closing") will involve the purchase of the remaining 27 cannabis retail stores, each of which are located in Ontario. The purchase price for the Second Closing will be $27.2 million cash, subject to certain adjustments at the time of the Second Closing. In addition, the outside date for completion of the 1CM Transaction has been extended from December 31, 2025 to May 31, 2026. The previously paid $1.0 million cash deposit from April 2025 will be applied towards the purchase price in respect of the Second Closing, which is still pending regulatory approval.

------

The 1CM Transaction is expected to strengthen the Company's financial condition as the addition of the 1CM Stores will increase the Company's exposure to a broad consumer base in key Canadian markets. The Company's financial performance and cash flows are projected to improve based on current 1CM store level operating results.

# OTHER DEVELOPMENTS
**U.S. TARIFFS**

In early 2025, the U.S. administration imposed certain tariffs on imports from certain countries, including Canada, and in response, the Canadian administration imposed their own tariffs on certain imports from the United States. Canada and the United States continue ongoing negotiations on a new trade and security relationship, though the scope and terms of such negotiations and the agreements they may produce, if any, are unknown. These tariff announcements and the risk of further potential retaliatory tariffs have created uncertainty, which has permeated the economic and investment outlook, impacting current economic conditions, including such issues as the inflation rate and the global supply chain. Aside from the impact on the global economy, these tariffs may continue to impact SNDL.

In response to tariffs imposed by the U.S., several Canadian provinces had taken retaliatory measures by removing U.S. alcohol from store shelves and restaurant, bar and retailer fulfillment catalogues. While some provinces, including Alberta, have lifted their ban on U.S. liquor imports, other provinces continue to impose the ban, despite the Canadian federal government lifting retaliatory tariffs on many U.S. goods.

SNDL is continuing to monitor the evolving situation and the impacts and potential consequences on its financial position. The Company did not experience a significant impact to its financial performance during the three months ended March 31, 2026.

**share repurchase program**

On November 3, 2025, the Company announced that the board of directors of the Company (the "Board") approved a renewal of the share repurchase program upon its expiry on November 20, 2025. On November 21, 2025, the Company announced that it had received approval from the CSE for the renewal of its share repurchase program. The share repurchase program authorizes the Company to repurchase up to $100 million of its outstanding common shares from time to time through open market purchases at prevailing market prices. SNDL may purchase up to a maximum of approximately 24.5 million common shares under the share repurchase program, representing approximately 10% of the issued and outstanding common shares as at the date of announcement, and will expire on November 20, 2026. The share repurchase program does not require the Company to purchase any minimum number of common shares and repurchases may be suspended or terminated at any time at the Company's discretion. The actual number of common shares which may be purchased pursuant to the share repurchase program and the timing of any purchases will be determined by SNDL's management and the Board. All common shares purchased pursuant to the share repurchase program will be returned to treasury for cancellation.

For the three months ended March 31, 2026, the Company purchased and cancelled 4.5 million common shares at a weighted average price, excluding commissions, of $2.13 (US$1.56) per common share for a total cost of $9.6 million including commissions.

Refer to "Liquidity and Capital Resources – Equity" below for further details regarding common shares purchased and cancelled.

------

# FINANCIAL HIGHLIGHTS
The following table summarizes selected financial information of the Company for the periods noted.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **($000s, except per share amounts)** | **Q1 2026** | **Q1 2025** | **Change** | **% Change** |
| **Financial Results** |  |  |  |  |
| Net revenue | **195906** | 204914 | (9008) | -4% |
| Cost of sales | **143094** | 148273 | (5179) | -3% |
| Gross profit | **52812** | 56641 | (3829) | -7% |
| Gross margin <sup>(1)</sup> | **27.0%** | 27.6% |  | -0.7% |
| Operating loss | **(9114)** | (12053) | 2939 | 24% |
| Adjusted operating loss <sup>(2)</sup> | **(8942)** | (9031) | 89 | 1% |
| Net loss attributable to owners of the Company | **(9911)** | (14707) | 4796 | 33% |
| &nbsp;&nbsp;&nbsp;&nbsp;Per share, basic and diluted | **(0.04)** | (0.06) | 0.02 | 33% |
| Change in cash and cash equivalents | **(26697)** | 2508 | (29205) | -1164% |
| Free cash flow <sup>(2)</sup> | **(7591)** | (1090) | (6501) | -596% |
| **Statement of Financial Position** |  |  |  |  |
| Cash and cash equivalents | **213404** | 220867 | (7463) | -3% |
| Inventory | **134982** | 132899 | 2083 | 2% |
| Right of use assets | **136852** | 111239 | 25613 | 23% |
| Property, plant and equipment | **149398** | 158129 | (8731) | -6% |
| Total assets | **1314639** | 1312273 | 2366 | 0% |

---

(1)Gross margin is a supplementary financial measure calculated by dividing gross profit by net revenue for the periods noted. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information.

(2)Adjusted operating income (loss) and free cash flow are specified financial measures that do not have standardized meanings prescribed by International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS Accounting Standards") and therefore may not be comparable to similar measures used by other companies. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information.

# CONSOLIDATED RESULTS
**General and administrative**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Salaries and wages | **28661** | 28430 |
| Consulting fees | **1732** | 2082 |
| Office and general | **11877** | 12152 |
| Professional fees | **1993** | 1504 |
| Merchant processing fees | **1522** | 1468 |
| Director fees | **222** | 241 |
| Other | **600** | 482 |
|  | **46607** | 46359 |

---

General and administrative expenses for the three months ended March 31, 2026 were $46.6 million compared to $46.4 million for the three months ended March 31, 2025. The increase of $0.2 million was mainly due to increases in professional fees and salaries and wages, partially offset by decreases in consulting fees and office and general expenses. The increase in professional fees was due to higher legal and accounting expenses. The increase in salaries and wages was due to severance costs recognized in the current period, partially offset by continued optimization of corporate overheads. Office and general expenses decreased due to less spending on office supplies and repairs and maintenance costs.

------

**Share-based compensation**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Equity-settled expense |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted share units | **1806** | 2459 |
| Cash-settled expense |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred share units | **(1190)** | (1071) |
|  | **616** | 1388 |

---

Share-based compensation expense includes the expense related to the Company's issuance of restricted share units ("RSUs") and deferred share units ("DSUs") to employees, directors, and others at the discretion of the Board. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company's common shares at each period end. Share-based compensation expense for the three months ended March 31, 2026 was $0.6 million compared to $1.4 million for the three months ended March 31, 2025. The decrease of $0.8 million was due to a decrease in RSU expense and a minor decrease in DSU expense. The decrease in RSU expense was caused by the vesting of RSUs granted in prior years and a decrease in the number and value of RSUs granted in the current year.

**Operating loss**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Operating loss | **(9114)** | (12053) |

---

Operating loss for the three months ended March 31, 2026 was $9.1 million compared to $12.1 million for the three months ended March 31, 2025. The decrease in operating loss of $3.0 million was due to an increase in share of profit of equity-accounted investees ($5.0 million) and decreases in share-based compensation expense ($0.8 million) and asset impairment ($2.2 million), partially offset by a decrease in gross profit ($3.8 million) and investment income ($1.4 million). The changes noted above are discussed in more detail throughout the relevant consolidated and segment results sections.

**Net loss**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Net loss | **(9911)** | (14707) |

---

Net loss for the three months ended March 31, 2026 was $9.9 million compared to $14.7 million for the three months ended March 31, 2025. The decrease in net loss of $4.8 million was largely due to an increase in share of profit of equity-accounted investees ($5.0 million) and income tax recovery ($1.5 million) and decreases in share-based compensation expense ($0.8 million) and asset impairment ($2.2 million), partially offset by a decrease in gross profit ($3.8 million) and investment income ($1.4 million). The changes noted above are discussed in more detail throughout the relevant consolidated and segment results sections.

# OPERATING SEGMENTS
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.

Liquor retail includes the sale of wines, beers and spirits through wholly owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis products and accessories through corporate-owned, controlled and franchised retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments

------

include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as "Corporate".

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Intersegment<br>Eliminations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** | **As at March 31, 2026** |
| Total assets | 206508 | 211380 |  | 417888 | 319076 | 410095 | 167580 | 1314639 |
| **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| Net revenue <sup>(1)</sup> | 77345 | 29432 | (14954) | 91823 | 104083 |  |  | 195906 |
| Gross profit | 20352 | 5802 |  | 26154 | 26658 |  |  | 52812 |
| Operating income (loss) | 1116 | (6942) |  | (5826) | (3160) | 2038 | (2166) | (9114) |
| Adjusted operating income (loss) <sup>(2)</sup> | 1116 | (6942) |  | (5826) | (3160) | 2038 | (1994) | (8942) |

---

(1)The Company has eliminated $15.0 million for the three months ended March 31, 2026 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.

(2)Adjusted operating income (loss) is a specified financial measure that does not have standardized meaning prescribed by IFRS Accounting Standards and therefore may not be comparable to similar measures used by other companies. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Intersegment<br>Eliminations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** | **As at December 31, 2025** |
| Total assets | 219462 | 211625 |  | 431087 | 324447 | 397537 | 182846 | 1335917 |
| **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| Net revenue <sup>(1)</sup> | 77540 | 34319 | (16417) | 95442 | 109472 |  |  | 204914 |
| Gross profit | 19627 | 9211 |  | 28838 | 27803 |  |  | 56641 |
| Operating income (loss) <sup>(2)</sup> | 1327 | (6171) |  | (4844) | (2417) | (1601) | (3191) | (12053) |
| Adjusted operating income (loss) <sup>(2)(3)</sup> | 1327 | (3276) |  | (1949) | (2417) | (1601) | (3064) | (9031) |

---

(1)The Company has eliminated $16.4 million for the three months ended March 31, 2025 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.

(2)Recast - refer to description below

(3)Adjusted operating income (loss) is a specified financial measure that does not have standardized meaning prescribed by IFRS Accounting Standards and therefore may not be comparable to similar measures used by other companies. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information.

In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

The following table presents the effect of the adjustments made to operating income (loss) and adjusted operating income (loss) for the periods indicated.

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Intersegment<br>Eliminations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| Operating income (loss) as previously reported | 5162 | (486) |  | 4676 | 1980 | (1601) | (17108) | (12053) |
| Adjustment to general and administrative expenses | (3835) | (5685) |  | (9520) | (4397) |  | 13917 |  |
| Operating income (loss) as recast | 1327 | (6171) |  | (4844) | (2417) | (1601) | (3191) | (12053) |
| Adjusted operating income (loss) as previously reported | 5162 | 2409 |  | 7571 | 1980 | (1601) | (16981) | (9031) |
| Adjustment to general and administrative expenses | (3835) | (5685) |  | (9520) | (4397) |  | 13917 |  |
| Adjusted operating income (loss) as recast | 1327 | (3276) |  | (1949) | (2417) | (1601) | (3064) | (9031) |

---

# LIQUOR RETAIL SEGMENT RESULTS
**Operating income (loss)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 | 2025 | 2025 |
|  |  | As Previously Reported | Adjustment <sup>(2)</sup> | As Recast |
| Net revenue | **104083** | 109472 |  | 109472 |
| Cost of sales | **77425** | 81669 |  | 81669 |
| Gross profit | **26658** | 27803 |  | 27803 |
| *Gross margin* <sup>(1)</sup> | ***25.6***<br>*%*** | *25.4%* |  | *25.4%* |
| General and administrative | **21013** | 16992 | 4397 | 21389 |
| Sales and marketing | **1227** | 775 |  | 775 |
| Depreciation and amortization | **7738** | 8098 |  | 8098 |
| Share-based compensation | **92** |  |  |  |
| Asset impairment (reversal) | **(171)** |  |  |  |
| Other income | **(81)** |  |  |  |
| (Gain) loss on disposition of assets | **—** | (42) |  | (42) |
| Operating income (loss) | **(3160)** | 1980 | (4397) | (2417) |

---

(1)Gross margin is a supplementary financial measure calculated by dividing gross profit by net revenue for the periods noted. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information.

(2)In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

Net revenue for the three months ended March 31, 2026 was $104.1 million compared to $109.5 million for the three months ended March 31, 2025. The decrease of $5.4 million was due to lower customer traffic reflecting declining market trends.

Cost of sales for the three months ended March 31, 2026 was $77.4 million compared to $81.7 million for the three months ended March 31, 2025. The decrease of $4.3 million was due to an overall decrease in sales as noted above.

------

Gross profit for the three months ended March 31, 2026 was $26.7 million (25.6%) compared to $27.8 million (25.4%) for the three months ended March 31, 2025. The decrease of $1.1 million was partly due to a reduction in net revenue and cost of sales noted above, partially offset by a continued focus on private label portfolio, pricing strategies and optimizing product discounts.

The increase in sales and marketing expense for the three months ended March 31, 2026 were mainly caused by new store marketing expenses.

During the three months ended March 31, 2026, the Company recorded impairment reversals on retail property, plant and equipment of $0.2 million due to improved store level operating results. During the three months ended March 31, 2025, no impairments or impairment reversals were recorded.

At April 28, 2026, the Ace Liquor store count was 133, the Liquor Depot store count was 19 and the Wine and Beyond store count was 15.

# CANNABIS RETAIL SEGMENT RESULTS
**Operating income (loss)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 | 2025 | 2025 |
|  |  | As Previously Reported | Adjustment <sup>(2)</sup> | As Recast |
| Net revenue | **77345** | 77540 |  | 77540 |
| Cost of sales | **56993** | 57913 |  | 57913 |
| Gross profit | **20352** | 19627 |  | 19627 |
| *Gross margin* <sup>(1)</sup> | ***26.3***<br>*%*** | *25.3%* |  | *25.3%* |
| General and administrative | **15214** | 11260 | 3835 | 15095 |
| Sales and marketing | **261** | 253 |  | 253 |
| Depreciation and amortization | **4230** | 3700 |  | 3700 |
| Share-based compensation | **39** |  |  |  |
| Asset (reversal) impairment | **(482)** | (731) |  | (731) |
| Loss on disposition of assets | **(26)** | (17) |  | (17) |
| Operating income (loss) | **1116** | 5162 | (3835) | 1327 |

---

(1)Gross margin is a supplementary financial measure calculated by dividing gross profit by net revenue for the periods noted. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information.

(2)In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

Net revenue for the three months ended March 31, 2026 was $77.3 million compared to $77.5 million for the three months ended March 31, 2025. The decrease of $0.2 million is mainly attributable to decreases in franchise revenue and proprietary licensing revenue, partially offset by a minor increase in retail sales.

Cost of sales for the three months ended March 31, 2026 was $57.0 million compared to $57.9 million for the three months ended March 31, 2025. The decrease of $0.9 million was due to a change in product mix from changing consumer preferences.

Gross profit for the three months ended March 31, 2026 was $20.4 million (26.3%) compared to $19.6 million (25.3%) for the three months ended March 31, 2025. The increase of $0.8 million was due to a change in product mix from changing consumer preferences.

The increase in general and administrative expenses for the three months ended March 31, 2026 was mainly due to severance costs, partially offset by continued optimization of corporate overheads.

------

During the three months ended March 31, 2026, the Company recorded impairment reversals on right of use assets of $0.3 million and retail property, plant and equipment of $0.2 million due to improved store level operating results. During the three months ended March 31, 2025, the Company recorded impairment reversals on right of use assets of $0.5 million and property, plant and equipment of $0.3 million due to improved store level operating results.

At April 28, 2026, the Spiritleaf store count was 61 (4 corporate stores and 57 franchise stores), the Value Buds store count was 127 corporate stores and the Cost Cannabis store count was 5.

# CANNABIS OPERATIONS SEGMENT RESULTS
**Operating income (loss)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 | 2025 | 2025 |
|  |  | As Previously Reported | Adjustment <sup>(2)</sup> | As Recast |
| Net revenue | **29432** | 34319 |  | 34319 |
| Cost of sales | **23630** | 25108 |  | 25108 |
| Gross profit | **5802** | 9211 |  | 9211 |
| *Gross margin* <sup>(1)</sup> | ***19.7***<br>*%*** | *26.8%* |  | *26.8%* |
| General and administrative | **9302** | 3524 | 5685 | 9209 |
| Sales and marketing | **2377** | 2406 |  | 2406 |
| Depreciation and amortization | **351** | 753 |  | 753 |
| Share-based compensation | **232** |  |  |  |
| Restructuring costs | **—** | 199 |  | 199 |
| Asset impairment | **475** | 2715 |  | 2715 |
| Research and development | **4** | 100 |  | 100 |
| (Gain) loss on disposition of assets | **3** |  |  |  |
| Operating income (loss) | **(6942)** | (486) | (5685) | (6171) |

---

(1)Gross margin is a supplementary financial measure calculated by dividing gross profit by net revenue for the periods noted. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information.

(2)In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

The Company's revenue comprises bulk and packaged sales under the Cannabis Act pursuant to its supply agreements with Canadian provincial boards, other licensed producers and international exports, proprietary extraction services, white label product formulation and manufacturing, the sale of bulk winterized oil and distillate, toll processing and co-packaging services and analytical testing.

Net revenue for the three months ended March 31, 2026 was $29.4 million compared to $34.3 million for the three months ended March 31, 2025. The decrease of $4.9 million was mainly due to decreases in sales to provincial boards and wholesale sales.

Cost of sales for the three months ended March 31, 2026 were $23.6 million compared to $25.1 million for the three months ended March 31, 2025. The decrease of $1.5 million was mainly due to the decrease in net revenue noted above, partially offset by an increase in inventory obsolescence of $0.9 million.

Gross profit for the three months ended March 31, 2026 was $5.8 million (19.7%) compared to $9.2 million (26.8%) for the three months ended March 31, 2025. The decrease of $3.4 million was due to the decrease in net revenue and cost of sales noted above and an increase in inventory obsolescence.

The increase in general and administrative expenses for the three months ended March 31, 2026 was mainly due to severance costs, partially offset by continued optimization of corporate overheads.

------

During the three months ended March 31, 2026, the Company recorded impairments on property, plant and equipment of $0.5 million due to slow moving market conditions. During the three months ended March 31, 2025, the Company recorded impairments on property, plant and equipment of $2.7 million due to the consolidation of the Company's edible facilities as part of its integration strategy.

# INVESTMENTS SEGMENT RESULTS
**Operating income (loss)**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Investment income | **1537** | 2856 |
| Share of profit (loss) of equity-accounted investees | **501** | (4457) |
| Operating income (loss) | **2038** | (1601) |

---

Investment income for the three months ended March 31, 2026 was $1.5 million compared to $2.9 million for the three months ended March 31, 2025. The decrease of $1.4 million was mainly due to lower interest income from investments at amortized cost, caused by the principal repayment of a $27 million commercial mortgage in March 2025.

Share of profit (loss) of equity-accounted investees is comprised of the Company's share of the net profit (or loss) generated from its investments in SunStream. The current investment portfolio of SunStream is comprised of secured debt, hybrid debt, derivative instruments and convertible equity instruments issued by United States based cannabis businesses.

Share of profit of equity-accounted investees for the three months ended March 31, 2026 was $0.5 million compared to loss of $4.5 million for the three months ended March 31, 2025. The increase of $5.0 million was mostly due to accounting fair value adjustments to the investments.

# SELECTED QUARTERLY INFORMATION
The following table summarizes selected consolidated operating and financial information of the Company for the preceding eight quarters.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **2026** | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
| **($000s, except per share amounts)** | **Q1** | **Q4** | **Q3** | **Q2** | **Q1** | **Q4** | **Q3** | **Q2** |
| Net revenue | 195906 | 252499 | 244219 | 244769 | 204914 | 257679 | 236892 | 228127 |
| Gross profit | 52812 | 70229 | 64177 | 67601 | 56641 | 68799 | 62968 | 58164 |
| Investment income | 1537 | 1652 | 1777 | 1529 | 2856 | 2734 | 5577 | 3204 |
| Net earnings (loss) attributable to owners of the Company <sup>(1)</sup> | (9911) | 9367 | (13319) | 2885 | (14707) | (67142) | (19328) | (5772) |
| &nbsp;&nbsp;&nbsp;&nbsp;Per share, basic and diluted <sup>(1)</sup> | (0.04) | 0.04 | (0.05) | 0.01 | (0.06) | (0.25) | (0.07) | (0.02) |

---

(1)These values are equal to values from "net earnings (loss) from continuing operations attributable to owners of the Company", in total and on a per-share and diluted per-share basis.

During the eight most recent quarters the following items have had a significant impact on the Company's financial results and results of operations:

• Impairment and impairment reversals on property, plant and equipment and right of use assets;

• Changes to provisions for inventory obsolescence and impairment;

• Investments in and distributions from SunStream;

• Acquisitions of Lightbox Enterprises Ltd. and Indiva Limited;

• Impairment of intangible assets from the cannabis retail cash generating unit ("CGU");

• Impairment of the Stellarton facility due to slow moving market conditions;

• Entering into and acquiring several cannabis-related investments;

• Repayment and exiting cannabis-related investments; and

------

• Increased net revenue and gross profit from acquisitions and organic growth, partially offset by a general decline in demand in the liquor industry and shifting consumer preferences in the cannabis industry.

# LIQUIDITY AND CAPITAL RESOURCES

---

| | | |
|:---|:---|:---|
| **($000s)** | **March 31, 2026** | December 31, 2025 |
| Cash and cash equivalents | **213404** | 252243 |

---

Capital resources are financing resources available to the Company and are defined as the Company's debt and equity. The Company manages its capital resources with the objective of maximizing shareholder value and sustaining future development of the business. The Company manages its capital structure and adjusts it, based on the funds available to the Company, in order to support the Company's activities. The Company may adjust capital spending, issue new equity or issue new debt, subject to the availability of such debt or equity financing on commercial terms.

The Company's primary need for liquidity is to fund investment opportunities, capital expenditures, working capital requirements and for general corporate purposes. The Company's working capital requirements are primarily driven by maintaining inventory levels, the extension of credit to customers and the settling of obligations with suppliers. The Company's primary source of liquidity historically has been from funds received from the proceeds of common share issuances and debt financing. The Company has generated positive operating cash flows and positive total change in cash and cash equivalents during the last two fiscal years. The Company's ability to fund operations and investments and make planned capital expenditures depends on future operating performance and cash flows, as well as the availability of future financing, all of which are subject to prevailing economic conditions and financial, business and other factors.

Management believes its current capital resources will be sufficient to satisfy cash requirements associated with funding the Company's operating expenses and future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

**Debt**

As at March 31, 2026, the Company had no outstanding bank debt or other debt.

**Equity**

As at March 31, 2026, the Company had the following share capital instruments outstanding:

---

| | | |
|:---|:---|:---|
| **(000s)** | **March 31, 2026** | December 31, 2025 |
| Common shares | **260171** | 263359 |
| Common share purchase warrants <sup>(1)</sup> | **54** | 54 |
| Simple warrants <sup>(2)</sup> | **16** | 16 |
| Performance warrants <sup>(3)</sup> | **8** | 21 |
| Stock options <sup>(4)</sup> | **84** | 321 |
| Restricted share units | **8689** | 6855 |

---

(1)54,400 warrants were exercisable as at March 31, 2026.

(2)16,000 simple warrants were exercisable as at March 31, 2026.

(3)No performance warrants were exercisable as at March 31, 2026.

(4)84,098 stock options were exercisable as at March 31, 2026.

The number of common shares outstanding changed during the three months ended March 31, 2026 in connection with the following transactions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Pursuant to the Company's share repurchase program, the Company purchased and cancelled 4.5 million common shares at a weighted average price, excluding commissions, of $2.13 (US$1.56) per common share for a total cost of $9.6 million including commissions; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The Company issued 1.3 million common shares in connection with the vesting of RSUs under its long term incentive plan.

As at April 28, 2026, a total of 260.3 million common shares were outstanding.

------

**Cash Flow Summary**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating activities | **3481** | 7788 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investing activities | **(11366)** | 17172 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing activities | **(18812)** | (22452) |
| Change in cash and cash equivalents | **(26697)** | 2508 |

---

**Cash Flow – Operating Activities**

Net cash provided by operating activities was $3.5 million for the three months ended March 31, 2026 compared to $7.8 million provided by operating activities for the three months ended March 31, 2025. The decrease of $4.3 million was due to a decrease in net loss and adjustments for non-cash items and unfavourable changes in working capital which resulted in cash outflows during the period. The change in non-cash working capital is comprised of changes in inventory, accounts receivable, prepaid expenses and deposits and accounts payable. Accounts receivable was impacted by the adoption of the IFRS 7 and IFRS 9 amendments, refer to "New Accounting Pronouncements" below for additional information.

**Cash Flow – Investing Activities**

Net cash used in investing activities was $11.4 million for the three months ended March 31, 2026 compared to $17.2 million provided by investing activities for the three months ended March 31, 2025. The decrease of $28.6 million was primarily due to lower principal payments from investments, capital contributions to equity-accounted investees (as compared to distributions in the prior period) and an increase in acquisitions, partially offset by lower additions to investments. During the three months ended March 31, 2025, the Company received the principal repayment of a $27 million commercial mortgage. The acquisition related to 1CM, refer to "Recent Developments – Acquisition of Cost Cannabis and T Cannabis locations from 1CM" above for further details.

**Cash Flow – Financing Activities**

Net cash used in financing activities was $18.8 million for the three months ended March 31, 2026 compared to $22.5 million used in financing activities for the three months ended March 31, 2025. The decrease of $3.7 million was largely due to a decrease in common shares repurchased, partially offset by an increase in lease payments.

**Free cash flow**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Free cash flow | **(7591)** | (1090) |

---

Free cash flow is a specified financial measure that does not have a standardized meaning prescribed by IFRS Accounting Standards and therefore may not be comparable to similar measures used by other companies. Refer to the "Non-IFRS Financial Measures and Other Measures" section of this MD&A for further information. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

Free cash flow was negative $7.6 million for the three months ended March 31, 2026 compared to negative $1.1 million for the three months ended March 31, 2025. The decrease of $6.5 million was mainly due to a decrease in net loss and adjustments for non-cash items, exercise of cash-settled DSUs, an increase in additions to property, plant and equipment and an increase in lease payments. The adjustments for non-cash items were mostly due to income tax recovery, change in fair value of biological assets and inventory sold, share-based compensation, inventory obsolescence and impairment, asset impairment and share of profit of equity-accounted investees.

------

**Financial Instruments**

Refer to note 22 in the Interim Financial Statements for additional information on the Company's financial instruments and the related fair value estimates and disclosures.

**Liquidity risks associated with financial instruments**

**Credit risk**

Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The maximum amount of the Company's credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable, and investments. The Company attempts to mitigate such exposure to its cash and cash equivalents by investing only in financial institutions with investment grade credit ratings or secured investments. The Company manages risk over its accounts receivable by issuing credit only to creditworthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company.

The Company applies the simplified approach under IFRS 9 for trade receivables by grouping receivables based on shared credit risk characteristics and the days past due. The expected loss rates are based on historical credit losses experienced over a period of 12 months.

The Company applies the general approach under IFRS 9 to other receivables and other investments, which is an assessment of whether the credit risk of a financial instrument has increased significantly since initial recognition.

**Liquidity risk**

Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. The Company prepares forecasts to ensure sufficient liquidity to fulfil obligations and operating plans. Management believes its current capital resources will be sufficient to satisfy cash requirements associated with funding the Company's operating expenses and future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

**Market risk**

Market risk is the risk that changes in market prices will affect the Company's income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company's marketable securities are shares of publicly traded entities.

**Regulatory risk**

Regulatory risk pertains to the risk that the Company's business objectives are contingent, in part, upon compliance with regulatory requirements. Due to the nature of the industries in which the Company operates, the Company recognizes that regulatory requirements are more stringent and punitive in nature than most other sectors of the economy. Any delays in obtaining, or failure to obtain, regulatory approvals could significantly delay operational and/or product development and could have a material adverse effect on the Company's business, results of operations, and financial condition. The Company is cognizant of the advent of regulatory changes in these industries on the city, provincial, and national levels in Canada and is aware of the effect that unforeseen regulatory changes in these industries could have on the goals and operations of the business as a whole.

------

# CONTRACTUAL COMMITMENTS AND CONTINGENCIES
**A)** **Commitments**

The information presented in the table below reflects management's estimate of the contractual maturities of the Company's obligations at March 31, 2026.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Less than<br>one year** | **One to three<br>years** | **Three to five<br>years** | **Thereafter** | **Total** |
| Accounts payable and accrued liabilities | 51799 |  |  |  | 51799 |
| Lease liabilities | 43711 | 72651 | 50174 | 11120 | 177656 |
| Financial guarantee liability |  | 135 |  |  | 135 |
| Loyalty liability |  | 388 |  |  | 388 |
| **Total** | **95510** | **73174** | **50174** | **11120** | **229978** |

---

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash.

The Company has entered into royalty agreements to pay a certain amount of royalties on cannabis products sold. Should the Company not sell sufficient product in the agreed timeframe, a minimal royalty payment is accrued.

**B)** **Contingencies**

From time to time, the Company and its subsidiaries are or may become involved in various legal claims and actions which arise in the ordinary course of their business and operations. While the outcome of any such claim or action is inherently uncertain, the Company believes that the losses that may result, if any, will not be material to the consolidated financial statements.

# NON-IFRS FINANCIAL MEASURES AND OTHER MEASURES
Certain specified financial measures in this MD&A including adjusted operating income (loss), free cash flow, same store sales and Adjusted EBITDA are non-IFRS measures. These terms are not defined by IFRS Accounting Standards and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for measures of performance prepared in accordance with IFRS Accounting Standards.

**GROSS MARGIN**

Gross margin is a supplementary financial measure calculated by dividing gross profit by net revenue for the periods noted.

**Adjusted operating income (loss)**

Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted operating income (loss) provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

------

The following tables reconcile adjusted operating income (loss) to operating income (loss) for the periods noted.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| Operating income (loss) | 1116 | (6942) | (5826) | (3160) | 2038 | (2166) | (9114) |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring costs |  |  |  |  |  | 172 | 172 |
| Adjusted operating income (loss) | **1116** | **(6942)** | **(5826)** | **(3160)** | **2038** | **(1994)** | **(8942)** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis<br>Retail** | **Cannabis<br>Operations** | **Cannabis<br>Total** | **Liquor<br>Retail** | **Investments** | **Corporate** | **Total** |
| **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| Operating income (loss) <sup>(1)</sup> | 1327 | (6171) | (4844) | (2417) | (1601) | (3191) | (12053) |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring costs |  | 199 | 199 |  |  | 127 | 326 |
| &nbsp;&nbsp;Impairments triggered by restructuring |  | 2696 | 2696 |  |  |  | 2696 |
| Adjusted operating income (loss) | **1327** | **(3276)** | **(1949)** | **(2417)** | **(1601)** | **(3064)** | **(9031)** |

---

(1)In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period. Refer to "Operating Segments" above for further details.

**Free cash flow**

Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance. Free cash flow provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Change in cash and cash equivalents | **(26697)** | 2508 |
| Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common shares | **9575** | 15031 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes to long-term investments | **6631** | (18629) |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions, net of cash acquired | **2900** |  |
| Free cash flow | **(7591)** | (1090) |

---

**Same store sales**

Same store sales is a supplementary financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's sales trends excluding the effect of the opening and closure of stores.

Same store sales refers to the revenue generated by the Company's existing retail locations during the current and prior comparison periods.

**ADJUSTED EBITDA**

Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company's

------

operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including enterprise resource planning ("ERP") implementation costs and litigation settlements, net of recoveries.

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br>March 31** | **Three months ended<br>March 31** |
| **($000s)** | **2026** | 2025 |
| Net earnings (loss) | **(9911)** | (14707) |
| Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory and biological assets fair value and impairment adjustments | **1630** | (520) |
| &nbsp;&nbsp;&nbsp;&nbsp;Share of (gain) loss of equity-accounted investees | **(501)** | 4457 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **12855** | 13228 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | **616** | 1388 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs | **172** | 326 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset impairment | **(178)** | 1984 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on disposition of PP&E | **(40)** | (59) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expenses, net | **2294** | 2654 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax recovery | **(1497)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-recurring items | **387** | 206 |
| Adjusted EBITDA | **5827** | 8957 |

---

# RELATED PARTIES
SunStream is a joint venture in which the Company has a 50% ownership interest and is a related party due to it being classified as a joint venture of the Company. SunStream is a private company, incorporated under the ABCA, which provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. Capital contributions to the joint venture and distributions received from the joint venture are classified as related party transactions.

# OFF BALANCE SHEET ARRANGEMENTS
As at March 31, 2026, the Company did not have any off-balance sheet arrangements.

# CRITICAL ACCOUNTING ESTIMATES
The Company makes assumptions in applying critical accounting estimates that are uncertain at the time the accounting estimate is made and may have a significant effect on its consolidated financial statements. Critical accounting estimates include the classification and recoverable amounts of CGUs, value of inventory, value of equity-accounted investees, value of leases, acquisitions and fair value of assets acquired and liabilities assumed in a business combination. Critical accounting estimates are based on variable inputs including but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Demand for cannabis for adult-use and medical purposes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Price of cannabis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Expected cannabis sales volumes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Demand for liquor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Price of liquor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Expected liquor sales volumes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Changes in market interest and discount rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Future development and operating costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Costs to convert harvested cannabis to finished goods;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Potential returns and pricing adjustments; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Market prices, volatility and discount rates used to determine fair value of equity-accounted investees.

Changes in critical accounting estimates can have a significant effect on profit or loss as a result of their impact on revenue, costs of sales, provisions and impairments. Changes in critical accounting estimates can have a significant effect on the valuation of inventory, property, plant and equipment, provisions and derivative financial instruments.

For a detailed discussion regarding the Company's critical accounting estimates, refer to the notes to the Audited Financial Statements.

# NEW ACCOUNTING PRONOUNCEMENTS
The International Accounting Standards Board and the IFRS Interpretations Committee regularly issue new and revised accounting pronouncements which have future effective dates and therefore are not reflected in the Company's consolidated financial statements. Once adopted, these new and amended pronouncements may have an impact on the Company's consolidated financial statements. The following accounting standard was effective for annual periods beginning on or after January 1, 2026 and had a material impact on the Company's consolidated financial statements:

**Classification and Measurement of Financial Instruments — Amendments to IFRS 9 and IFRS 7**

On January 1, 2026, the Company adopted the amendments to IFRS 9 and IFRS 7 using the prospective application. The amendments include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Clarification on the date of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic payment system.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Clarification and further guidance for assessing whether a financial asset meets the solely payments of principal and interest criterion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•New disclosure requirements for certain instruments without contractual terms that can change cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Updates to the disclosure required for equity instruments designated at fair value through other comprehensive income.

**Impact on adoption**

At March 31, 2026, there was a $5.7 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, which is reflected in the statement of financial position and statement of cash flows. The Company estimated the impact to be approximately $12.1 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, had the amendments been in effect for the annual period ending December 31, 2025.

There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2027, discussed below, which have not been applied in preparing the consolidated financial statements for the three months ended March 31, 2026.

**IFRS 18 Presentation and Disclosure in Financial Statements**

IFRS 18 will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after January 1, 2027. The new accounting standard introduces the following key new requirements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Entities are required to classify all income and expenses into five categories in the statement of profit or loss, namely the operating, investing, financing, discontinued operations and income tax categories. Entities are also required to present a newly-defined operating profit subtotal. Entities' net profit will not change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Management-defined performance measures are disclosed in a single note in the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Enhanced guidance is provided on how to group information in the financial statements.

In addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method.

The Company is still in the process of assessing the impact of the new accounting standard, particularly with respect to the structure of the Company's statement of profit or loss, the statement of cash flows and the additional disclosures required for management-defined performance measures.

------

**Other accounting standards**

The following new and amended accounting standards are not expected to have a material impact on the Company's consolidated financial statements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•IFRS 19 Subsidiaries without Public Accountability: Disclosures

# RISK FACTORS
In addition to the risks described elsewhere in this document, for a detailed discussion regarding the Company's risk factors, refer to the "Risk Factors" section of the AIF.

# DISCLOSURE CONTROLS AND PROCEDURES
The Company has designed disclosure controls and procedures (as defined in National Instrument – *Certification of Disclosure in Issuers' Annual and Interim Filings* ("NI 52-109") and Rules 13a-15(f) and 15d-15(f) under the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act")) to provide reasonable assurance that: (i) material information relating to the Company is made known to the Company's Chief Executive Officer and Chief Financial Officer by others, particularly during the period in which the annual and interim filings are being prepared; and (ii) information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time period specified in such securities legislation.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026. Based upon evaluation of the Company's disclosure controls and procedures as of March 31, 2026, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026.

# INTERNAL CONTROL OVER FINANCIAL REPORTING
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in NI 52-109 and Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Refer to our MD&A for the year ended December 31, 2025, for a discussion regarding our internal control over financial reporting and the remediation of a previously identified material weakness.

# CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no other changes in our internal control over financial reporting (as defined in NI 52-109 and Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

# ABBREVIATIONS
The following provides a summary of common abbreviations used in this document:

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Financial and Business Environment** | &nbsp;&nbsp;**Financial and Business Environment** |
| &nbsp;&nbsp;$ or C$ | &nbsp;&nbsp;Canadian dollars |
| &nbsp;&nbsp;U.S. | &nbsp;&nbsp;United States |
| &nbsp;&nbsp;US$ | &nbsp;&nbsp;United States dollars |

---

------

# FORWARD-LOOKING INFORMATION
This MD&A may contain forward-looking information concerning the Company's business, operations and financial performance and condition, as well as the Company's plans, objectives and expectations for its business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim", "anticipate", "assume", "believe", "contemplate", "continue", "could", "due", "estimate", "expect", "goal", "intend", "may", "objective", "plan", "predict", "potential", "positioned", "pioneer", "seek", "should", "target", "will", "would", and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the anticipated benefits of and the Company's intentions with respect to the Rise Rewards loyalty program and its expansion across retail banners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the uncertainties associated with tariffs and countermeasures thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•expectations with respect to retail and investment operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•expectations with respect to the 1CM Transaction, including the satisfaction of certain regulatory approvals and the anticipated timing of the Second Closing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the anticipated benefits to the Company with respect to the 1CM Transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's intentions with respect to the Cost Cannabis and T Cannabis brands and integration with SNDL;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of tariffs on the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the expected benefits of the CSE listing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•expectations with respect to the Company's restructuring project;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•expectations with respect to the Company's joint venture interest in SunStream;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of consolidating cannabis segments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's share repurchase program;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to adjust its capital resources;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's liquidity needs, including its ability to source its liquidity requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the sufficiency of the Company's capital resources;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•risks associated with financial instruments and the methods by which the Company manages such risks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•expectations with respect to various contingencies, including the impact of such on the Company's financial statements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of changes to critical accounting estimates and new accounting pronouncements; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•expectations with respect to remediation measures to control deficiencies.

Although the forward-looking statements contained in this MD&A are based on assumptions that the Company believes are reasonable, you are cautioned that actual results and developments (including Company results of operations, financial condition and liquidity, and the development of the industry in which the Company operates) may differ materially from those made in or suggested by the forward-looking statements contained in this MD&A. In addition, even if results and developments are consistent with the forward-looking statements contained in this MD&A, those results and developments may not be indicative of results or developments in subsequent periods.

Certain assumptions made in preparing the forward-looking statements contained in this MD&A include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to implement its operational and liquidity strategies as well as its strategic initiatives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's competitive advantages;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of competition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the changes and trends in the cannabis cultivation and retail, and the liquor retail industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in laws, rules and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to maintain and renew required licences;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to maintain good business relationships with its customers, distributors and other strategic partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to keep pace with changing consumer preferences;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to protect its intellectual property;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to identify, finance and consummate acquisitions on attractive terms, integrate acquired companies and to realize the benefits of such acquisitions, including The Valens Company Inc. and the 1CM stores;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to retain key personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to efficiently deploy capital and achieve its expected and desired returns on such investments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to maintain and keep its public listing on the Nasdaq and the CSE and the liquidity of the trading of its common shares on a publicly listed stock exchange;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Company's ability to open new retail locations and attract a sufficient number of qualified franchisees; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the absence of material adverse changes in the Company's industry or the global economy, including as a result of global economic downturns.

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company's business and the industry in which it operates and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. As a result, any or all of the forward-looking information in this MD&A may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled "Risk Factors" in the AIF and otherwise described in this MD&A. Readers of this MD&A are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this MD&A and, except as required by applicable law, the Company assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with applicable securities regulators, including the Canadian securities regulators and the U.S. Securities and Exchange Commission (the "SEC"), after the date of this MD&A.

This MD&A contains estimates, projections and other information concerning the Company's industry, its business and the markets for its products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from its own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. Certain statements included in this MD&A may be considered "financial outlook" for purposes of applicable securities laws, and such financial outlook may not be appropriate for purposes other than this MD&A. The purpose of the financial outlook is to provide readers with disclosure of the Company's reasonable expectations of its anticipated results. The financial outlook is provided as of the date of this MD&A.

In addition, assumptions and estimates of the Company's and industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled "Risk Factors" in the AIF and elsewhere in this MD&A. These and other factors could cause the Company's future performance to differ materially from the Company's assumptions and estimates. Readers of this MD&A are cautioned against placing undue reliance on forward-looking statements.

Further information regarding the assumptions and risks inherent in the making of forward-looking statements can be found in the AIF, along with the Company's other public disclosure documents. Copies of the AIF and other public disclosure documents are available under the Company's profile on the System for Electronic Data Analysis and Retrieval + ("SEDAR+") at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov.

# ADDITIONAL INFORMATION
Additional information relating to the Company, including the Company's most recent AIF, can be viewed under the Company's profile on SEDAR+ at www.sedarplus.ca, on the EDGAR section of the SEC's website at www.sec.gov, or on the Company's website at www.sndl.com. The information on or accessible through our website is not part of and is not incorporated by reference into this MD&A, and the inclusion of our website address in this MD&A is only for reference.

------

## Exhibit 99.3

**EXHIBIT 99.3**

**Form 52-109F2**

***Certification of Interim Filings***

***Full Certificate***

I, Zachary George, Chief Executive Officer of SNDL Inc., certify the following:

1. ***Review:*** I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of SNDL Inc. (the "issuer") for the interim period ended March 31, 2026.

2. ***No misrepresentations:*** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3.***Fair presentation:*** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4.***Responsibility:*** The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers' Annual and Interim Filings,* for the issuer.

5.***Design:*** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 ***Control framework:*** The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is "Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)".

------

5.2 ***ICFR – material weakness relating to design:*** The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a description of the material weakness; <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.

5.3 ***Limitation on scope of design:*** N/A

6. ***Reporting changes in ICFR:*** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2026 and ended on March 31, 2026 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: April 28, 2026

/s/ Zachary George

_______________________

Zachary George

Chief Executive Officer

------

## Exhibit 99.4

**EXHIBIT 99.4**

**Form 52-109F2**

***Certification of Interim Filings***

***Full Certificate***

I, Alberto Paredero Quiros, Chief Financial Officer of SNDL Inc., certify the following:

1. ***Review:*** I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of SNDL Inc. (the "issuer") for the interim period ended March 31, 2026.

2. ***No misrepresentations:*** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3.***Fair presentation:*** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4.***Responsibility:*** The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers' Annual and Interim Filings,* for the issuer.

5.***Design:*** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 ***Control framework:*** The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is "Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)".

------

5.2 ***ICFR – material weakness relating to design:*** The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a description of the material weakness; <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.

5.3 ***Limitation on scope of design:*** N/A

6. ***Reporting changes in ICFR:*** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2026 and ended on March 31, 2026 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: April 28, 2026

/s/ Alberto Paredero Quiros

_______________________

Alberto Paredero Quiros

Chief Financial Officer

------